Quiñonero, G.; Gallo, J.; Carrasco, A.; Samitier, J.; Villasante, A. Engineering Biomimetic Nanoparticles through Extracellular Vesicle Coating in Cancer Tissue Models. Nanomaterials2023, 13, 3097.
Quiñonero, G.; Gallo, J.; Carrasco, A.; Samitier, J.; Villasante, A. Engineering Biomimetic Nanoparticles through Extracellular Vesicle Coating in Cancer Tissue Models. Nanomaterials 2023, 13, 3097.
Quiñonero, G.; Gallo, J.; Carrasco, A.; Samitier, J.; Villasante, A. Engineering Biomimetic Nanoparticles through Extracellular Vesicle Coating in Cancer Tissue Models. Nanomaterials2023, 13, 3097.
Quiñonero, G.; Gallo, J.; Carrasco, A.; Samitier, J.; Villasante, A. Engineering Biomimetic Nanoparticles through Extracellular Vesicle Coating in Cancer Tissue Models. Nanomaterials 2023, 13, 3097.
Abstract
Using nanoparticles (NPs) in drug delivery has exhibited promising therapeutic potential 13 in various cancer types. Nevertheless, several challenges must be addressed, including the 14 formation of the protein corona, reduced targeting efficiency and specificity, potential immune 15 responses, and issues related to NP penetration and distribution within 3-dimensional tissues. 16 To tackle these challenges, we have successfully integrated iron oxide nanoparticles into 17 neuroblastoma-derived extracellular vesicles (EVs) using the parental labeling method. We first de- 18 veloped a tissue-engineered (TE) neuroblastoma model, confirming the viability and proliferation 19 of neuroblastoma cells for at least 12 days, supporting its utility for EV isolation. Importantly, EVs 20 from long-term cultures exhibited no differences compared to short-term cultures. Concurrently, 21 we designed Rhodamine (Rh), Polyacrylic acid (PAA)-functionalized magnetite nanoparticles 22 (Fe3O4@PAA-Rh) with high crystallinity, purity, and superparamagnetic properties (average size: 23 9.2 ± 2.5 nm). We then investigated the internalization of Fe3O4@PAA-Rh nanoparticles within 24 neuroblastoma cells within the TE model. Maximum accumulation was observed overnight while 25 ensuring robust cell viability. However, nanoparticle internalization was low. Taking advantage of 26 the enhanced glucose metabolism exhibited by cancer cells, glucose (Glc)-functionalized nanoparti- 27 cles (Fe3O4@PAA-Rh-Glc) were synthesized, showing superior cell uptake within the 3D model 28 without inducing toxicity. These glucose-modified nanoparticles were selected for parental labeling 29 of the TE models, showing effective NPs encapsulation into EVs. 30 Our research introduces innovative approaches to advance NPs delivery. By partially addressing 31 the challenges associated with 3D systems, optimizing internalization, and enhancing NPs stability 32 and specificity through EV-based carriers. Also, our findings hold the promise of more precise and 33 effective cancer therapies while minimizing potential side effects.
Keywords
neuroblastoma; extracellular vesicles; iron oxide nanoparticles; biomimetic models; precision medicine
Subject
Chemistry and Materials Science, Nanotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
